首页 > 最新文献

Scandinavian Journal of Urology最新文献

英文 中文
The influence of secondary resection using NeuroSAFE-technique on sexual function in unilateral nerve-sparing robot-assisted laparoscopic prostatectomies. 神经安全技术对单侧保留神经的机器人辅助腹腔镜前列腺切除术中性功能的影响。
IF 1.5 4区 医学 Q3 UROLOGY & NEPHROLOGY Pub Date : 2023-08-28 DOI: 10.2340/sju.v58.6234
Mirjam Naomi Mohr, Annemarie Uhlig, Hannah Maria Ploeger, Oliver Hahn, Lutz Trojan, Mathias Reichert

Objective: To demonstrate the surgical influence of secondary resection on sexual function in finally unilateral nerve-sparing robot- assisted laparoscopic prostatectomies (RALPs) performed with the 'neurovascular structure-adjacent frozen-section examination' (NeuroSAFE) technique by prospectively collecting EPIC-26-questionnaires.

Material & methods: Sexual function status measured by the sexual-symptom-score (SexSS) in the EPIC-26-questionnaires was collected preoperatively and 12 months after RALP from 378 patients between 09/2019 and 04/2021. Cohorts of interest were defined as those patients undergoing unilateral nerve-sparing by secondary resection of the other neurovascular bundle (NVB), and as those patients undergoing primarily planned and successful unilateral nerve-sparing (unilateral nerve-sparing without secondary resection) in ≤cT2 prostate cancer. NeuroSAFE frozen section technique was performed in all nerve-sparing RALPs, and in case of cancer-positive surgical margins, the complete NVB was resected.

Results: In 109 RALPs with unilateral nerve-sparing (48 primarily vs. 61 by secondary resection), analyses showed a significant difference in postoperative SexSS for 'unilateral nerve-sparing by secondary resection' compared with 'unilateral nerve-sparing without secondary resection' (43 [interquartile range (IQR): 14;50] vs. 26 [IQR: 22;62], P = 0.04). In multivariable analyses, the preoperative SexSS was predictive for postoperative erectile dysfunction (OR = 0.96, 95% confidence interval: 0.93-0.98, P < 0.001). Oncological safety was not compromised by secondary resection (prostate-specific antigen after 12 months 0.01 ng/mL vs. 0.01 ng/mL [P = 0.3] for unilateral nerve-sparing by secondary resection vs. unilateral nerve-sparing without secondary resection).

Conclusion: The results of this study suggest that nerve-sparing attempts applying the NeuroSAFEtechnique should be generously performed since a unilateral complete secondary resection leading to a unilateral nerve-sparing RALP did not seem to have a negative influence on sexual function and did not seem to compromise oncological safety compared with primarily performed and successful unilateral nerve-sparing RALP.

目的:通过对epic -26问卷的前瞻性收集,探讨保留神经的机器人辅助腹腔镜前列腺切除术(RALPs)中二次切除对性功能的影响。材料与方法:收集2019年9月至2021年4月期间378例患者术前和RALP后12个月的性功能状况,采用epic -26问卷中的性症状评分(SexSS)进行测量。感兴趣的队列定义为那些通过二次切除其他神经血管束(NVB)进行单侧神经保留的患者,以及那些在≤cT2前列腺癌中进行主要计划和成功的单侧神经保留(单侧神经保留而不进行二次切除)的患者。所有保留神经的ralp均采用NeuroSAFE冷冻切片技术,如果手术切缘呈癌阳性,则全部切除NVB。结果:在109例保留单侧神经的ralp中(48例主要保留单侧神经,61例经二次切除),分析显示“经二次切除保留单侧神经”与“不经二次切除保留单侧神经”的术后SexSS有显著差异(43例[四分位间距(IQR): 14;50]对26例[IQR: 22;62], P = 0.04)。在多变量分析中,术前的SexSS可以预测术后勃起功能障碍(OR = 0.96, 95%可信区间:0.93-0.98,P < 0.001)。肿瘤安全性不受二次切除的影响(12个月后前列腺特异性抗原0.01 ng/mL vs. 0.01 ng/mL [P = 0.3],单侧神经保留经二次切除vs.单侧神经保留不经二次切除)。结论:本研究的结果表明,应用神经安全技术的神经保留尝试应该大量进行,因为与主要实施和成功的单侧神经保留RALP相比,单侧完全二次切除导致单侧神经保留RALP似乎没有对性功能产生负面影响,并且似乎没有损害肿瘤安全性。
{"title":"The influence of secondary resection using NeuroSAFE-technique on sexual function in unilateral nerve-sparing robot-assisted laparoscopic prostatectomies.","authors":"Mirjam Naomi Mohr,&nbsp;Annemarie Uhlig,&nbsp;Hannah Maria Ploeger,&nbsp;Oliver Hahn,&nbsp;Lutz Trojan,&nbsp;Mathias Reichert","doi":"10.2340/sju.v58.6234","DOIUrl":"https://doi.org/10.2340/sju.v58.6234","url":null,"abstract":"<p><strong>Objective: </strong>To demonstrate the surgical influence of secondary resection on sexual function in finally unilateral nerve-sparing robot- assisted laparoscopic prostatectomies (RALPs) performed with the 'neurovascular structure-adjacent frozen-section examination' (NeuroSAFE) technique by prospectively collecting EPIC-26-questionnaires.</p><p><strong>Material & methods: </strong>Sexual function status measured by the sexual-symptom-score (SexSS) in the EPIC-26-questionnaires was collected preoperatively and 12 months after RALP from 378 patients between 09/2019 and 04/2021. Cohorts of interest were defined as those patients undergoing unilateral nerve-sparing by secondary resection of the other neurovascular bundle (NVB), and as those patients undergoing primarily planned and successful unilateral nerve-sparing (unilateral nerve-sparing without secondary resection) in ≤cT2 prostate cancer. NeuroSAFE frozen section technique was performed in all nerve-sparing RALPs, and in case of cancer-positive surgical margins, the complete NVB was resected.</p><p><strong>Results: </strong>In 109 RALPs with unilateral nerve-sparing (48 primarily vs. 61 by secondary resection), analyses showed a significant difference in postoperative SexSS for 'unilateral nerve-sparing by secondary resection' compared with 'unilateral nerve-sparing without secondary resection' (43 [interquartile range (IQR): 14;50] vs. 26 [IQR: 22;62], P = 0.04). In multivariable analyses, the preoperative SexSS was predictive for postoperative erectile dysfunction (OR = 0.96, 95% confidence interval: 0.93-0.98, P < 0.001). Oncological safety was not compromised by secondary resection (prostate-specific antigen after 12 months 0.01 ng/mL vs. 0.01 ng/mL [P = 0.3] for unilateral nerve-sparing by secondary resection vs. unilateral nerve-sparing without secondary resection).</p><p><strong>Conclusion: </strong>The results of this study suggest that nerve-sparing attempts applying the NeuroSAFEtechnique should be generously performed since a unilateral complete secondary resection leading to a unilateral nerve-sparing RALP did not seem to have a negative influence on sexual function and did not seem to compromise oncological safety compared with primarily performed and successful unilateral nerve-sparing RALP.</p>","PeriodicalId":21542,"journal":{"name":"Scandinavian Journal of Urology","volume":"58 ","pages":"60-67"},"PeriodicalIF":1.5,"publicationDate":"2023-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10493026","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Primary mucosal melanomas of the urogenital tract: a clinical, pathological, and genetic nationwide survey of Danish patients 1990-2019. 泌尿生殖道原发性粘膜黑色素瘤:1990-2019年丹麦患者的临床、病理和遗传全国调查
IF 1.5 4区 医学 Q3 UROLOGY & NEPHROLOGY Pub Date : 2023-08-27 DOI: 10.2340/sju.v58.8489
Victoria K Znaider, Lauge H Mikkelsen, Christian Fuglesang S Jensen, Jens Sønksen, Steffen Heegaard

Purpose: To describe the epidemiologic, clinical, histopathological, and genetic features of primary mucosal melanoma of the urinary tract in a national Danish cohort with cases included from the year 1990 to 2019.

Material and methods: Patients of the Danish cohort were found using national databases. Only primary tumours were included in the cohort. Appropriate formalin-fixed paraffin-embedded blocks underwent next-generation sequencing.

Results: Eight cases of primary urinary bladder melanomas and 18 cases of primary urethral melanomas were included. Bladder melanomas had an incidence of 0.05 cases/million/year. Mean age at diagnosis was 67 years. The most frequent primary treatment was cystectomy. Adjuvant treatment was given in three cases and consisted of chemotherapy or radiotherapy. Mutations were found in the NF1, KRAS, ATRX, TP53, RAC1, and BRAF genes. Urethral melanomas were found to have an incidence of 0.12 cases/million/year. Average age at diagnosis was 77 years. The most frequent treatment was excision of the tumour. Adjuvant treatment was given in nine cases and most frequently consisted of radiotherapy. Mutations were found in the NF1, TERT PROMOTOR, NRAS, ATRX, TP53, ATM, TSC2, and CREBBP genes. The 5-year survival of patients with bladder melanoma was 12.5% and 22.2% for patients with urethral melanoma.

Conclusion: Our study highlights the rarity of urinary tract melanomas and their poor prognosis. The most widely used treatment for urogenital mucosal melanoma remains surgical while adjuvant therapy strategies are evolving. Next-generation sequencing showed mutational patterns with no location-specific patterns. The most frequent mutations were in the NF1, ATRX, NRAS, and TP53 genes.

目的:描述1990年至2019年丹麦国家队列病例中尿路原发性粘膜黑色素瘤的流行病学、临床、组织病理学和遗传特征。材料和方法:从国家数据库中找到丹麦队列的患者。只有原发性肿瘤被纳入队列。适当的福尔马林固定石蜡包埋块进行下一代测序。结果:原发性膀胱黑色素瘤8例,原发性尿道黑色素瘤18例。膀胱黑色素瘤发病率为0.05例/百万/年。诊断时的平均年龄为67岁。最常见的主要治疗是膀胱切除术。辅助治疗3例,包括化疗或放疗。在NF1、KRAS、ATRX、TP53、RAC1和BRAF基因中发现了突变。尿道黑色素瘤的发病率为0.12例/百万/年。确诊时的平均年龄为77岁。最常用的治疗方法是切除肿瘤。辅助治疗9例,最常见的是放疗。在NF1、TERT启动子、NRAS、ATRX、TP53、ATM、TSC2和CREBBP基因中发现了突变。膀胱黑色素瘤患者的5年生存率为12.5%,尿道黑色素瘤患者的5年生存率为22.2%。结论:我们的研究强调了泌尿道黑色素瘤的罕见性和预后差。泌尿生殖粘膜黑色素瘤最广泛使用的治疗方法仍然是手术,而辅助治疗策略也在不断发展。下一代测序显示突变模式没有位置特异性模式。最常见的突变发生在NF1、ATRX、NRAS和TP53基因。
{"title":"Primary mucosal melanomas of the urogenital tract: a clinical, pathological, and genetic nationwide survey of Danish patients 1990-2019.","authors":"Victoria K Znaider,&nbsp;Lauge H Mikkelsen,&nbsp;Christian Fuglesang S Jensen,&nbsp;Jens Sønksen,&nbsp;Steffen Heegaard","doi":"10.2340/sju.v58.8489","DOIUrl":"https://doi.org/10.2340/sju.v58.8489","url":null,"abstract":"<p><strong>Purpose: </strong>To describe the epidemiologic, clinical, histopathological, and genetic features of primary mucosal melanoma of the urinary tract in a national Danish cohort with cases included from the year 1990 to 2019.</p><p><strong>Material and methods: </strong>Patients of the Danish cohort were found using national databases. Only primary tumours were included in the cohort. Appropriate formalin-fixed paraffin-embedded blocks underwent next-generation sequencing.</p><p><strong>Results: </strong>Eight cases of primary urinary bladder melanomas and 18 cases of primary urethral melanomas were included. Bladder melanomas had an incidence of 0.05 cases/million/year. Mean age at diagnosis was 67 years. The most frequent primary treatment was cystectomy. Adjuvant treatment was given in three cases and consisted of chemotherapy or radiotherapy. Mutations were found in the NF1, KRAS, ATRX, TP53, RAC1, and BRAF genes. Urethral melanomas were found to have an incidence of 0.12 cases/million/year. Average age at diagnosis was 77 years. The most frequent treatment was excision of the tumour. Adjuvant treatment was given in nine cases and most frequently consisted of radiotherapy. Mutations were found in the NF1, TERT PROMOTOR, NRAS, ATRX, TP53, ATM, TSC2, and CREBBP genes. The 5-year survival of patients with bladder melanoma was 12.5% and 22.2% for patients with urethral melanoma.</p><p><strong>Conclusion: </strong>Our study highlights the rarity of urinary tract melanomas and their poor prognosis. The most widely used treatment for urogenital mucosal melanoma remains surgical while adjuvant therapy strategies are evolving. Next-generation sequencing showed mutational patterns with no location-specific patterns. The most frequent mutations were in the NF1, ATRX, NRAS, and TP53 genes.</p>","PeriodicalId":21542,"journal":{"name":"Scandinavian Journal of Urology","volume":"58 ","pages":"52-59"},"PeriodicalIF":1.5,"publicationDate":"2023-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10481372","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A randomised study of TURP after intraprostatic injection of mepicacaine/adrenaline versus regular TURP in patients with LUTS/BPO. LUTS/BPO患者前列腺内注射美哌卡因/肾上腺素后与常规TURP的随机研究
IF 1.5 4区 医学 Q3 UROLOGY & NEPHROLOGY Pub Date : 2023-08-24 DOI: 10.2340/sju.v58.7798
Fredrik Stenmark, Lars Brundin, Olof Gunnarsson, Henrik Kjölhede, Edvard Lekås, Ralph Peeker, Marianne Månsson, Jonas Richthoff, Johan Stranne

Introduction: During transurethral resection of the prostate (TURP), the most established surgical treatment of lower urinary tract symptoms (LUTS) due to benign prostatic obstruction (BPO), the prostate can bleed profusely, bringing about anaemia and compromised oxygen delivery to the entire body.

Objective: The primary objective of this study was to assess the efficacy of mepivacaine and adrenaline (MA) injected into the prostate on bleeding. The primary endpoint was to measure blood loss per resected weight of prostate tissue.

Material and methods: This randomised controlled trial evaluated 81 patients with LUTS/BPO. Patients were randomly allocated to regular TURP or TURP with intraprostatic injections of MA.

Results: On univariable analyses there was a significant difference in resection weight in favour of the experimental group, not reflected by a statistically significant difference in the other studied outcome parameters. Nevertheless, in multivariable analyses, blood loss per resection weight, which was the primary outcome, showed a significant decrease in favour of the experimental group. Clavien-Dindo complication classification showed three men with a grade I complication and two men with grade II.

Conclusions: The results obtained in this study showed that it is beneficial to apply intraprostatic injections of MA in immediate conjunction with TURP, in terms of blood loss per resected gram. The study is, however, small and corroboration of our results in more extensive prospective studies may therefore be warranted before embarking upon this technique.

导言:经尿道前列腺切除术(TURP)是治疗良性前列腺梗阻(BPO)引起的下尿路症状(LUTS)最成熟的手术治疗方法,前列腺可大量出血,导致贫血和全身氧气输送受损。目的:本研究的主要目的是评估前列腺注射甲哌卡因和肾上腺素(MA)对出血的疗效。主要终点是测量每切除前列腺组织重量的失血量。材料和方法:该随机对照试验评估了81例LUTS/BPO患者。患者被随机分配到常规TURP组或前列腺内注射MA的TURP组。结果:在单变量分析中,实验组的切除重量有显著差异,但其他研究结果参数没有统计学上的显著差异。然而,在多变量分析中,每切除重量的失血量,这是主要结局,显示实验组显著减少。Clavien-Dindo并发症分级显示3例患者为I级并发症,2例患者为II级并发症。结论:本研究的结果表明,就每克切除的出血量而言,前列腺内注射MA与TURP立即联合使用是有益的。然而,这项研究规模较小,因此,在开始使用这项技术之前,可能需要在更广泛的前瞻性研究中证实我们的结果。
{"title":"A randomised study of TURP after intraprostatic injection of mepicacaine/adrenaline versus regular TURP in patients with LUTS/BPO.","authors":"Fredrik Stenmark,&nbsp;Lars Brundin,&nbsp;Olof Gunnarsson,&nbsp;Henrik Kjölhede,&nbsp;Edvard Lekås,&nbsp;Ralph Peeker,&nbsp;Marianne Månsson,&nbsp;Jonas Richthoff,&nbsp;Johan Stranne","doi":"10.2340/sju.v58.7798","DOIUrl":"https://doi.org/10.2340/sju.v58.7798","url":null,"abstract":"<p><strong>Introduction: </strong>During transurethral resection of the prostate (TURP), the most established surgical treatment of lower urinary tract symptoms (LUTS) due to benign prostatic obstruction (BPO), the prostate can bleed profusely, bringing about anaemia and compromised oxygen delivery to the entire body.</p><p><strong>Objective: </strong>The primary objective of this study was to assess the efficacy of mepivacaine and adrenaline (MA) injected into the prostate on bleeding. The primary endpoint was to measure blood loss per resected weight of prostate tissue.</p><p><strong>Material and methods: </strong>This randomised controlled trial evaluated 81 patients with LUTS/BPO. Patients were randomly allocated to regular TURP or TURP with intraprostatic injections of MA.</p><p><strong>Results: </strong>On univariable analyses there was a significant difference in resection weight in favour of the experimental group, not reflected by a statistically significant difference in the other studied outcome parameters. Nevertheless, in multivariable analyses, blood loss per resection weight, which was the primary outcome, showed a significant decrease in favour of the experimental group. Clavien-Dindo complication classification showed three men with a grade I complication and two men with grade II.</p><p><strong>Conclusions: </strong>The results obtained in this study showed that it is beneficial to apply intraprostatic injections of MA in immediate conjunction with TURP, in terms of blood loss per resected gram. The study is, however, small and corroboration of our results in more extensive prospective studies may therefore be warranted before embarking upon this technique.</p>","PeriodicalId":21542,"journal":{"name":"Scandinavian Journal of Urology","volume":"58 ","pages":"46-51"},"PeriodicalIF":1.5,"publicationDate":"2023-08-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10056203","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Predictors for complication in renal cancer surgery: a national register study. 肾癌手术并发症的预测因素:一项国家登记研究。
IF 1.5 4区 医学 Q3 UROLOGY & NEPHROLOGY Pub Date : 2023-08-21 DOI: 10.2340/sju.v58.12356
John Åkerlund, Pernilla Sundqvist, Börje Ljungberg, Sven Lundstam, Ralph Peeker, Marianne Månsson, Anna Grenabo Bergdahl

Objective: Nationwide register data provide unique opportunities for real-world assessment of complications from different surgical methods. This study aimed to assess incidence of, and predictors for, post-operative complications and to evaluate 90-day mortality  following different surgical procedures and thermal ablation for renal cell carcinoma (RCC).

Material and methods: All patients undergoing surgical treatment and thermal ablation for RCC in Sweden during 2015-2019 were identified from the National Swedish Kidney Cancer Register. Frequencies and types of post-operative complications were analysed. Logistic regression models were used to identify predictors for 90-day major (Clavien-Dindo grades III-V) complications, including death.

Results: The overall complication rate was 24% (1295/5505), of which 495 (8.7%) were major complications. Most complications occurred following open surgery, of which bleeding and infection were the most common. Twice as many complications were observed in patients undergoing open surgery compared to minimally invasive surgery (20% vs. 10%, P < 0.001). Statistically significant predictors for major complications irrespective of surgical category and technique were American society of anesthiologists (ASA) score, tumour diameter and serum creatinine. Separating radical and partial nephrectomy, surgical technique remained a significant risk factor for major complications. Most complications occurred within the first 20 days. The overall 90-day readmission rate was 6.2%, and 30- and 90-day mortality rates were 0.47% and 1.5%, respectively.

Conclusions: In conclusion, bleeding and infection were the most common major complications after RCC surgery. Twice as many patients undergoing open surgery suffer a major post-operative complication as compared to patients subjected to minimally invasive surgery. General predictors for major complications were ASA score, tumour size, kidney function and surgical technique.

目的:全国范围内的登记数据为评估不同手术方法的并发症提供了独特的机会。本研究旨在评估肾细胞癌(RCC)术后并发症的发生率和预测因素,并评估不同手术方式和热消融后的90天死亡率。材料和方法:2015-2019年期间在瑞典接受RCC手术治疗和热消融的所有患者均来自瑞典国家肾癌登记处。分析术后并发症的发生频率和类型。使用Logistic回归模型确定90天主要(Clavien-Dindo分级III-V)并发症(包括死亡)的预测因子。结果:总并发症发生率为24%(1295/5505),其中严重并发症495例(8.7%)。并发症多发生在开放性手术后,以出血和感染最为常见。开放性手术的并发症是微创手术的两倍(20% vs. 10%, P < 0.001)。美国麻醉医师协会(ASA)评分、肿瘤直径和血清肌酐是与手术类别和技术无关的主要并发症的有统计学意义的预测因子。将全肾切除术和部分肾切除术分开,手术技术仍然是主要并发症的重要危险因素。大多数并发症发生在前20天。总体90天再入院率为6.2%,30天和90天死亡率分别为0.47%和1.5%。结论:出血和感染是RCC术后最常见的主要并发症。与微创手术患者相比,接受开放手术的患者出现主要术后并发症的人数是前者的两倍。主要并发症的一般预测因子为ASA评分、肿瘤大小、肾功能和手术技术。
{"title":"Predictors for complication in renal cancer surgery: a national register study.","authors":"John Åkerlund,&nbsp;Pernilla Sundqvist,&nbsp;Börje Ljungberg,&nbsp;Sven Lundstam,&nbsp;Ralph Peeker,&nbsp;Marianne Månsson,&nbsp;Anna Grenabo Bergdahl","doi":"10.2340/sju.v58.12356","DOIUrl":"https://doi.org/10.2340/sju.v58.12356","url":null,"abstract":"<p><strong>Objective: </strong>Nationwide register data provide unique opportunities for real-world assessment of complications from different surgical methods. This study aimed to assess incidence of, and predictors for, post-operative complications and to evaluate 90-day mortality  following different surgical procedures and thermal ablation for renal cell carcinoma (RCC).</p><p><strong>Material and methods: </strong>All patients undergoing surgical treatment and thermal ablation for RCC in Sweden during 2015-2019 were identified from the National Swedish Kidney Cancer Register. Frequencies and types of post-operative complications were analysed. Logistic regression models were used to identify predictors for 90-day major (Clavien-Dindo grades III-V) complications, including death.</p><p><strong>Results: </strong>The overall complication rate was 24% (1295/5505), of which 495 (8.7%) were major complications. Most complications occurred following open surgery, of which bleeding and infection were the most common. Twice as many complications were observed in patients undergoing open surgery compared to minimally invasive surgery (20% vs. 10%, P < 0.001). Statistically significant predictors for major complications irrespective of surgical category and technique were American society of anesthiologists (ASA) score, tumour diameter and serum creatinine. Separating radical and partial nephrectomy, surgical technique remained a significant risk factor for major complications. Most complications occurred within the first 20 days. The overall 90-day readmission rate was 6.2%, and 30- and 90-day mortality rates were 0.47% and 1.5%, respectively.</p><p><strong>Conclusions: </strong>In conclusion, bleeding and infection were the most common major complications after RCC surgery. Twice as many patients undergoing open surgery suffer a major post-operative complication as compared to patients subjected to minimally invasive surgery. General predictors for major complications were ASA score, tumour size, kidney function and surgical technique.</p>","PeriodicalId":21542,"journal":{"name":"Scandinavian Journal of Urology","volume":"58 ","pages":"38-45"},"PeriodicalIF":1.5,"publicationDate":"2023-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10434478","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Abstract book for the 34th Congress of the Scandinavian Association of Urology (NUF). 第34届斯堪的纳维亚泌尿外科协会(NUF)大会摘要书。
IF 1.5 4区 医学 Q3 UROLOGY & NEPHROLOGY Pub Date : 2023-08-13 DOI: 10.2340/sju.v58.18375

June 7-10th, 2023 Bergen, Norway.

2023年6月7日至10日,卑尔根,挪威。
{"title":"Abstract book for the 34th Congress of the Scandinavian Association of Urology (NUF).","authors":"","doi":"10.2340/sju.v58.18375","DOIUrl":"https://doi.org/10.2340/sju.v58.18375","url":null,"abstract":"<p><p>June 7-10th, 2023 Bergen, Norway.</p>","PeriodicalId":21542,"journal":{"name":"Scandinavian Journal of Urology","volume":"58 ","pages":"1-48"},"PeriodicalIF":1.5,"publicationDate":"2023-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9989906","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Fluoroquinolone-resistant Escherichia coli among the rectal flora is the predominant risk factor for severe infection after transrectal ultrasound-guided prostate biopsy: a prospective observational study. 直肠菌群中氟喹诺酮耐药大肠杆菌是经直肠超声引导前列腺活检后严重感染的主要危险因素:一项前瞻性观察研究。
IF 1.5 4区 医学 Q3 UROLOGY & NEPHROLOGY Pub Date : 2023-08-08 DOI: 10.2340/sju.v58.11920
Martin Holmbom, Jon Forsberg, Mats Fredrikson, Maud Nilsson, Lennart E Nilsson, Håkan Hanberger, Anita Hällgren

Background: Infection of the prostate gland following biopsy, usually with Escherichia coli, is a common complication, despite the use of antimicrobial prophylaxis. A fluoroquinolone (FQ) is commonly prescribed as prophylaxis. Worryingly, the rate of fluoroquinolone-resistant (FQ-R) E. coli species has been shown to be increasing.

Objective: This study aimed to identify risk factors associated with infection after transrectal ultrasound-guided prostate biopsy (TRUS-Bx).

Methods: This was a prospective study on patients undergoing TRUS-Bx in southeast Sweden. Prebiopsy rectal and urine cultures were obtained, and antimicrobial susceptibility and risk-group stratification were determined. Multivariate analyses were performed to identify independent risk factors for post-biopsy urinary tract infection (UTI) and FQ-R E. coli in the rectal flora.

Results: In all, 283 patients were included, of whom 18 (6.4%) developed post-TRUS-Bx UTIs. Of these, 10 (3.5%) had an UTI without systemic inflammatory response syndrome (SIRS) and 8 (2.8%) had a UTI with SIRS. Being in the medium- or high-risk groups of infectious complications was not an independent risk factor for UTI with SIRS after TRUS-Bx, but low-level FQ-resistance (minimum inhibitory concentration (MIC): 0.125-0.25 mg/L) or FQ-resistance (MIC > 0.5 mg/L) among E. coli in the faecal flora was. Risk for SIRS increased in parallel with increasing degrees of FQ-resistance. Significant risk factor for harbouring FQ-R E.coli was travelling outside Europe within the previous 12 months.

Conclusion: The predominant risk factor for UTI with SIRS after TRUS-Bx was FQ-R E. coli among the faecal flora. The difficulty in identifying this type of risk factor demonstrates a need for studies on the development of a general approach either with rectal swab culture for targeted prophylaxis, or prior rectal preparation with a bactericidal agent such as povidone-iodine before TRUS-Bx to reduce the risk of FQ-R E. coli-related infection.

背景:活检后前列腺感染,通常伴有大肠杆菌,是一种常见的并发症,尽管使用了抗菌素预防。氟喹诺酮(FQ)通常作为预防处方。令人担忧的是,对氟喹诺酮类药物耐药(FQ-R)的大肠杆菌种类的比例已显示出正在增加。目的:本研究旨在确定经直肠超声引导前列腺活检(truss - bx)后感染的相关危险因素。方法:这是一项对瑞典东南部接受TRUS-Bx治疗的患者进行的前瞻性研究。活检前进行直肠和尿液培养,并确定抗菌素敏感性和风险组分层。进行多变量分析以确定活检后尿路感染(UTI)和直肠菌群中FQ-R大肠杆菌的独立危险因素。结果:共纳入283例患者,其中18例(6.4%)发生了trus - bx后尿路感染。其中,10例(3.5%)有无系统性炎症反应综合征(SIRS)的尿路感染,8例(2.8%)有伴系统性炎症反应综合征的尿路感染。感染并发症的中高危人群并不是TRUS-Bx后UTI合并SIRS的独立危险因素,但粪便菌群中大肠杆菌低水平的fq耐药(最低抑制浓度(MIC): 0.125-0.25 mg/L)或fq耐药(MIC > 0.5 mg/L)才是UTI合并SIRS的独立危险因素。SIRS的风险随着fq耐药程度的增加而增加。携带FQ-R型大肠杆菌的重要危险因素是在过去12个月内离开欧洲。结论:粪便菌群中FQ-R大肠杆菌是感染TRUS-Bx后UTI合并SIRS的主要危险因素。识别这类危险因素的困难表明,需要研究开发一种通用方法,要么通过直肠棉签培养进行有针对性的预防,要么在使用TRUS-Bx之前事先用消毒剂(如聚维酮碘)进行直肠准备,以降低FQ-R大肠杆菌相关感染的风险。
{"title":"Fluoroquinolone-resistant Escherichia coli among the rectal flora is the predominant risk factor for severe infection after transrectal ultrasound-guided prostate biopsy: a prospective observational study.","authors":"Martin Holmbom,&nbsp;Jon Forsberg,&nbsp;Mats Fredrikson,&nbsp;Maud Nilsson,&nbsp;Lennart E Nilsson,&nbsp;Håkan Hanberger,&nbsp;Anita Hällgren","doi":"10.2340/sju.v58.11920","DOIUrl":"https://doi.org/10.2340/sju.v58.11920","url":null,"abstract":"<p><strong>Background: </strong>Infection of the prostate gland following biopsy, usually with Escherichia coli, is a common complication, despite the use of antimicrobial prophylaxis. A fluoroquinolone (FQ) is commonly prescribed as prophylaxis. Worryingly, the rate of fluoroquinolone-resistant (FQ-R) E. coli species has been shown to be increasing.</p><p><strong>Objective: </strong>This study aimed to identify risk factors associated with infection after transrectal ultrasound-guided prostate biopsy (TRUS-Bx).</p><p><strong>Methods: </strong>This was a prospective study on patients undergoing TRUS-Bx in southeast Sweden. Prebiopsy rectal and urine cultures were obtained, and antimicrobial susceptibility and risk-group stratification were determined. Multivariate analyses were performed to identify independent risk factors for post-biopsy urinary tract infection (UTI) and FQ-R E. coli in the rectal flora.</p><p><strong>Results: </strong>In all, 283 patients were included, of whom 18 (6.4%) developed post-TRUS-Bx UTIs. Of these, 10 (3.5%) had an UTI without systemic inflammatory response syndrome (SIRS) and 8 (2.8%) had a UTI with SIRS. Being in the medium- or high-risk groups of infectious complications was not an independent risk factor for UTI with SIRS after TRUS-Bx, but low-level FQ-resistance (minimum inhibitory concentration (MIC): 0.125-0.25 mg/L) or FQ-resistance (MIC > 0.5 mg/L) among E. coli in the faecal flora was. Risk for SIRS increased in parallel with increasing degrees of FQ-resistance. Significant risk factor for harbouring FQ-R E.coli was travelling outside Europe within the previous 12 months.</p><p><strong>Conclusion: </strong>The predominant risk factor for UTI with SIRS after TRUS-Bx was FQ-R E. coli among the faecal flora. The difficulty in identifying this type of risk factor demonstrates a need for studies on the development of a general approach either with rectal swab culture for targeted prophylaxis, or prior rectal preparation with a bactericidal agent such as povidone-iodine before TRUS-Bx to reduce the risk of FQ-R E. coli-related infection.</p>","PeriodicalId":21542,"journal":{"name":"Scandinavian Journal of Urology","volume":"58 ","pages":"32-37"},"PeriodicalIF":1.5,"publicationDate":"2023-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10337065","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Long-term patient follow-up should be routinely implemented in radiotherapy units to detect late adverse effects after cancer treatment. 放疗单位应定期对患者进行长期随访,以发现癌症治疗后的晚期不良反应。
IF 1.5 4区 医学 Q3 UROLOGY & NEPHROLOGY Pub Date : 2023-08-07 DOI: 10.2340/sju.v58.13470
Kirsti Aas, Amir Sherif

Editorial comment to Urosymphyseal fistula after pelvic radiotherapy - an entity in patients with significant comorbidity requiring multidisciplinary management Scand J Urol. 2023.

盆腔放射治疗后尿联合瘘——一个需要多学科治疗的显著合并症患者的实体[J] .中国泌尿外科杂志。2023。
{"title":"Long-term patient follow-up should be routinely implemented in radiotherapy units to detect late adverse effects after cancer treatment.","authors":"Kirsti Aas,&nbsp;Amir Sherif","doi":"10.2340/sju.v58.13470","DOIUrl":"https://doi.org/10.2340/sju.v58.13470","url":null,"abstract":"<p><p>Editorial comment to Urosymphyseal fistula after pelvic radiotherapy - an entity in patients with significant comorbidity requiring multidisciplinary management Scand J Urol. 2023.</p>","PeriodicalId":21542,"journal":{"name":"Scandinavian Journal of Urology","volume":"58 ","pages":"30-31"},"PeriodicalIF":1.5,"publicationDate":"2023-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10316299","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Taking the temperature: a case of urethral polyembolokoilamania. 测体温:尿道多栓子症1例。
IF 1.5 4区 医学 Q3 UROLOGY & NEPHROLOGY Pub Date : 2023-07-10 DOI: 10.2340/sju.v58.7125
Kristian Lyngholm Strand, Jan Maciej Krzak
CONTACT Kristian Lyngholm Strand kristian.strand@rsyd.dk Fruerstuevej 21, 5700 Svendborg, Denmark. *Equally contributed. © 2023 The Author(s). Published by Medical Journals Sweden on behalf of Acta Chirurgica Scandinavica. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc-nd/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work. CASE REPORT
{"title":"Taking the temperature: a case of urethral polyembolokoilamania.","authors":"Kristian Lyngholm Strand,&nbsp;Jan Maciej Krzak","doi":"10.2340/sju.v58.7125","DOIUrl":"https://doi.org/10.2340/sju.v58.7125","url":null,"abstract":"CONTACT Kristian Lyngholm Strand kristian.strand@rsyd.dk Fruerstuevej 21, 5700 Svendborg, Denmark. *Equally contributed. © 2023 The Author(s). Published by Medical Journals Sweden on behalf of Acta Chirurgica Scandinavica. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc-nd/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work. CASE REPORT","PeriodicalId":21542,"journal":{"name":"Scandinavian Journal of Urology","volume":"58 ","pages":"28-29"},"PeriodicalIF":1.5,"publicationDate":"2023-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9812227","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Current evidence for moderate and ultra-hypofractionated radiation therapy in prostate cancer: a summary of the results from phase 3 randomised trials. 中度和超低分割放射治疗前列腺癌的现有证据:来自3期随机试验的结果总结
IF 1.5 4区 医学 Q3 UROLOGY & NEPHROLOGY Pub Date : 2023-06-20 DOI: 10.2340/sju.v58.7719
Oscar Lilleby, Peter Meidahl Petersen, Gedske Daugaard, Katharina Anne Perell

Problem: A low α/β ratio for prostate cancer (PCa) compared to surrounding normal tissue theoretically implies therapeutical advantages with hypofractionated treatment. Data from large randomised control trials (RCTs) comparing moderate hypofractionated (MHRT, 2.4-3.4 Gray/fraction (Gy/fx)) and ultra-hypofractionated (UHRT, >5 Gy/fx) with conventionally fractionated radiation therapy (CFRT, 1.8-2 Gy/fx) and the possible clinical implications have been reviewed.

Materials and method: We searched PubMed, Cochrane and Scopus for RCT comparing MHRT/UHRT with CFRT treatment of locally and/or locally advanced (N0M0) PCa. We found six RCTs, which compared different radiation therapy regimes. Tumour control and acute and late toxicities are reported.

Results: MHRT was non-inferior to CFRT for intermediate-risk PCa, non-inferior for low-risk PCa and not superior in terms of tumour control for high-risk PCa. Acute toxicity rates were increased compared to CFRT, especially an increase in acute gastrointestinal adverse effects was seen. Late toxicity related to MHRT seems to be comparable. UHRT was non-inferior in terms of tumour control in one RCT, with increased acute toxicity, but with comparable late toxicity. One trial, however, indicated increased late toxicity rates with UHRT.

Discussion and conclusion: MHRT delivers similar therapeutic outcomes compared to CFRT in terms of tumour control and late toxicity for intermediate-risk PCa patients. Slightly more acute transient toxicity could be tolerated in favour of a shorter treatment course. UHRT should be regarded as an optional treatment for patients with low- and intermediate-risk disease applied at experienced centres in concordance with international and national guidelines.

问题:与周围正常组织相比,前列腺癌(PCa)的低α/β比值理论上意味着低分割治疗的治疗优势。来自大型随机对照试验(rct)的数据,比较中度低分割(MHRT, 2.4-3.4 Gray/fraction (Gy/fx))和超低分割(UHRT, >5 Gy/fx)与常规分割放射治疗(CFRT, 1.8-2 Gy/fx)以及可能的临床意义。材料和方法:我们检索PubMed、Cochrane和Scopus,比较MHRT/UHRT与CFRT治疗局部和/或局部晚期(N0M0) PCa的RCT。我们发现了六项随机对照试验,比较了不同的放射治疗方案。肿瘤控制和急性和晚期毒性均有报道。结果:MHRT在中危PCa中不逊于CFRT,在低危PCa中不逊于CFRT,在高危PCa的肿瘤控制方面不优于CFRT。与CFRT相比,急性毒性发生率增加,特别是急性胃肠道不良反应增加。与MHRT相关的晚期毒性似乎具有可比性。在一项RCT中,UHRT在肿瘤控制方面并不逊色,急性毒性增加,但晚期毒性相当。然而,一项试验表明,UHRT增加了晚期毒性率。讨论和结论:与CFRT相比,MHRT在中度风险PCa患者的肿瘤控制和晚期毒性方面提供了相似的治疗结果。稍急性的短暂毒性可以耐受,有利于较短的疗程。UHRT应被视为低风险和中等风险疾病患者的一种可选治疗方法,在有经验的中心按照国际和国家准则实施。
{"title":"Current evidence for moderate and ultra-hypofractionated radiation therapy in prostate cancer: a summary of the results from phase 3 randomised trials.","authors":"Oscar Lilleby,&nbsp;Peter Meidahl Petersen,&nbsp;Gedske Daugaard,&nbsp;Katharina Anne Perell","doi":"10.2340/sju.v58.7719","DOIUrl":"https://doi.org/10.2340/sju.v58.7719","url":null,"abstract":"<p><strong>Problem: </strong>A low α/β ratio for prostate cancer (PCa) compared to surrounding normal tissue theoretically implies therapeutical advantages with hypofractionated treatment. Data from large randomised control trials (RCTs) comparing moderate hypofractionated (MHRT, 2.4-3.4 Gray/fraction (Gy/fx)) and ultra-hypofractionated (UHRT, >5 Gy/fx) with conventionally fractionated radiation therapy (CFRT, 1.8-2 Gy/fx) and the possible clinical implications have been reviewed.</p><p><strong>Materials and method: </strong>We searched PubMed, Cochrane and Scopus for RCT comparing MHRT/UHRT with CFRT treatment of locally and/or locally advanced (N0M0) PCa. We found six RCTs, which compared different radiation therapy regimes. Tumour control and acute and late toxicities are reported.</p><p><strong>Results: </strong>MHRT was non-inferior to CFRT for intermediate-risk PCa, non-inferior for low-risk PCa and not superior in terms of tumour control for high-risk PCa. Acute toxicity rates were increased compared to CFRT, especially an increase in acute gastrointestinal adverse effects was seen. Late toxicity related to MHRT seems to be comparable. UHRT was non-inferior in terms of tumour control in one RCT, with increased acute toxicity, but with comparable late toxicity. One trial, however, indicated increased late toxicity rates with UHRT.</p><p><strong>Discussion and conclusion: </strong>MHRT delivers similar therapeutic outcomes compared to CFRT in terms of tumour control and late toxicity for intermediate-risk PCa patients. Slightly more acute transient toxicity could be tolerated in favour of a shorter treatment course. UHRT should be regarded as an optional treatment for patients with low- and intermediate-risk disease applied at experienced centres in concordance with international and national guidelines.</p>","PeriodicalId":21542,"journal":{"name":"Scandinavian Journal of Urology","volume":"58 ","pages":"21-27"},"PeriodicalIF":1.5,"publicationDate":"2023-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9672252","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Response to M. Brehmer: Register-based research. Accurate data and analysis, crucial for correct conclusions. Comment on 'Incidence, mortality, and relative survival of patients with cancer of the bladder and upper urothelial tract in the Nordic countries between 1990 and 2019'. 对Brehmer先生的回应:基于注册的研究。准确的数据和分析,对正确的结论至关重要。对“1990年至2019年北欧国家膀胱癌和上尿路癌患者的发病率、死亡率和相对生存率”的评论。
IF 1.5 4区 医学 Q3 UROLOGY & NEPHROLOGY Pub Date : 2023-06-01 DOI: 10.2340/sju.v58.10299
Eemil Karttunen, Jan Oldenburg, Steinar Thoresen, Anders Ullén
{"title":"Response to M. Brehmer: Register-based research. Accurate data and analysis, crucial for correct conclusions. Comment on 'Incidence, mortality, and relative survival of patients with cancer of the bladder and upper urothelial tract in the Nordic countries between 1990 and 2019'.","authors":"Eemil Karttunen,&nbsp;Jan Oldenburg,&nbsp;Steinar Thoresen,&nbsp;Anders Ullén","doi":"10.2340/sju.v58.10299","DOIUrl":"https://doi.org/10.2340/sju.v58.10299","url":null,"abstract":"","PeriodicalId":21542,"journal":{"name":"Scandinavian Journal of Urology","volume":"58 ","pages":"20"},"PeriodicalIF":1.5,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9631529","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Scandinavian Journal of Urology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1